Gemcitabine resistance in triple‑negative breast cancer cells can be reverted by <em>Drosophila melanogaster</em> deoxyribonucleoside kinase in the nucleus or cytosol

Zhao,Yan; Jiang,Haiyang; Gu,Ming; Zu,Cong; Zheng,Xinyu

doi:10.3892/ol.2020.12109

Gemcitabine resistance in triple‑negative breast cancer cells can be reverted by Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol

Authors:
- Yan Zhao
- Haiyang Jiang
- Ming Gu
- Cong Zu
- Xinyu Zheng
View Affiliations

Affiliations: Department of Breast Surgery, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P.R. China, Lab 1, Cancer Institute, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: September 15, 2020 https://doi.org/10.3892/ol.2020.12109
Article Number: 247
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The development of drug resistance to chemotherapeutic agents has consistently presented a challenge in terms of the treatment of patients with triple‑negative breast cancer (TNBC). In the present study, gemcitabine (dFdC)‑resistant TNBC cells were established, and the effects of lentivirus‑deoxyribonucleoside kinase (dNK) and a mutated form of dNK (lentivirus‑dNKmut) on reversing the acquired drug resistance in dFdC‑resistant TNBC cells were explored. Quantitative PCR and western blotting experiment results suggested that Drosophila melanogaster (Dm)‑dNK was stably expressed in the lentivirus‑infected MDA‑MB‑231 and MDA-MB-231R cells in the nucleus or cytosol, and autoradiography experiments revealed similar levels of enzymatic activity in the cells expressing dNK or dNKmut. In vitro cytotoxicity assay revealed that the IC50 values of dFdC were decreased 30~50‑fold in the dFdC‑resistant MDA‑MB‑231 cells following lentiviral transfection with dNK or dNKmut, and this effect was associated with a significantly increased rate of apoptosis compared with the cells transfected with the negative control lentivirus. In conclusion, Dm‑dNK in the nucleus or cytosol may be a potential candidate for reversing acquired dFdC resistance in TNBC cells, which may form the basis of novel strategies for the treatment of patients with drug‑resistant TNBC.

View Figures

View References

1	Peddi PF, Ellis MJ and Ma C: Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer. 2012:2171852012. View Article : Google Scholar : PubMed/NCBI
2	Thomas H and Coley HM: Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 10:159–165. 2003. View Article : Google Scholar : PubMed/NCBI
3	Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007. View Article : Google Scholar : PubMed/NCBI
4	Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: Therapeutic options. Lancet Oncol. 8:235–244. 2007. View Article : Google Scholar : PubMed/NCBI
5	Garrido-Castro AC, Lin NU and Polyak K: Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment. Cancer Discov. 9:176–198. 2019. View Article : Google Scholar : PubMed/NCBI
6	Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, et al: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
7	Rong D, Wang C, Zhang X, Wei Y, Zhang M, Liu D, Farhan H, Ali SA, Liu Y, Taouil A, et al: A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells. Cancer Lett. 491:36–39. 2020. View Article : Google Scholar : PubMed/NCBI
8	Yuan D, Zhou H, Sun H, Tian R, Xia M, Sun L and Liu Y: Identification of key genes for guiding chemotherapeutic management in ovarian cancer using translational bioinformatics. Oncol Lett. 20:1345–1359. 2020. View Article : Google Scholar : PubMed/NCBI
9	Niero EL, Rocha-Sales B, Lauand C, Cortez BA, de Souza MM, Rezende-Teixeira P, Urabayashi MS, Martens AA, Neves JH and Machado-Santelli GM: The multiple facets of drug resistance: One history, different approaches. J Exp Clin Cancer Res. 33:372014. View Article : Google Scholar : PubMed/NCBI
10	Zhou M, Li L, Li L, Lin X, Wang F, Li Q and Huang Y: Overcoming chemotherapy resistance via simultaneous drug-efflux circumvention and mitochondrial targeting. Acta Pharm Sin B. 9:615–625. 2019. View Article : Google Scholar : PubMed/NCBI
11	Agarwal R and Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 3:502–516. 2003. View Article : Google Scholar : PubMed/NCBI
12	Asleh K, Lyck Carstensen S, Tykjaer Jørgensen CL, Burugu S, Gao D, Won JR, Jensen MB, Balslev E, Laenkholm AV, Nielsen DL, et al: Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial. Int J Cancer. 144:2578–2586. 2019. View Article : Google Scholar : PubMed/NCBI
13	Diéras V, Bonnefoi H, Alba E, Awada A, Coudert B, Pivot X, Gligorov J, Jager A, Zambelli S, Lindeman GJ, et al: Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: A phase II randomized open-label study with pharmacokinetics. Breast Cancer Res Treat. 177:383–393. 2019. View Article : Google Scholar : PubMed/NCBI
14	Spratlin JL and Mackey JR: Human equilibrative nucleoside transporter 1 (hENT1) in pancreatic adenocarcinoma: Towards individualized treatment decisions. Cancers (Basel). 2:2044–2054. 2010. View Article : Google Scholar : PubMed/NCBI
15	Hung SW, Marrache S, Cummins S, Bhutia YD, Mody H, Hooks SB, Dhar S and Govindarajan R: Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: Overcoming transport defects using a nanoparticle approach. Cancer Lett. 359:233–240. 2015. View Article : Google Scholar : PubMed/NCBI
16	Honeywell RJ, Ruiz van Haperen VW, Veerman G, Smid K and Peters GJ: Inhibition of thymidylate synthase by 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine) and its metabolite 2′,2′-difluoro-2′-deoxyuridine. Int J Biochem Cell Biol. 60:73–81. 2015. View Article : Google Scholar : PubMed/NCBI
17	Mitsuno M, Kitajima Y, Ohtaka K, Kai K, Hashiguchi K, Nakamura J, Hiraki M, Noshiro H and Miyazaki K: Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1. Int J Oncol. 36:341–349. 2010.PubMed/NCBI
18	Bergman AM, Pinedo HM and Peters GJ: Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 5:19–33. 2002. View Article : Google Scholar : PubMed/NCBI
19	Baker JA, Wickremsinhe ER, Li CH, Oluyedun OA, Dantzig AH, Hall SD, Qian YW, Ring BJ, Wrighton SA and Guo Y: Pharmacogenomics of gemcitabine metabolism: Functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug Metab Dispos. 41:541–545. 2013. View Article : Google Scholar : PubMed/NCBI
20	Garcia-Diaz M, Murray MS, Kunkel TA and Chou KM: Interaction between DNA polymerase lambda and anticancer nucleoside analogs. J Biol Chem. 285:16874–16879. 2010. View Article : Google Scholar : PubMed/NCBI
21	Galmarini CM, Clarke ML, Santos CL, Jordheim L, Perigaud C, Gosselin G, Cros E, Mackey JR and Dumontet C: Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue. Int J Cancer. 107:149–154. 2003. View Article : Google Scholar : PubMed/NCBI
22	Réjiba S, Bigand C, Parmentier C and Hajri A: Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia. 11:637–650. 2009. View Article : Google Scholar : PubMed/NCBI
23	Saiki Y, Yoshino Y, Fujimura H, Manabe T, Kudo Y, Shimada M, Mano N, Nakano T, Lee Y, Shimizu S, et al: DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem Biophys Res Commun. 421:98–104. 2012. View Article : Google Scholar : PubMed/NCBI
24	Wang Q, Yang M, Zhang Y, Zhong L and Zheng X: Novel combination oncolytic adenoviral gene therapy armed with Dm-dNK and CD40L for breast cancer. Curr Gene Ther. 19:54–65. 2019. View Article : Google Scholar : PubMed/NCBI
25	Dong X, Qu W, Ma S, Zhu Z, Zheng C, He A, Karlsson A, Xu K and Zheng X: Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo. Cancer Lett. 328:95–103. 2013. View Article : Google Scholar : PubMed/NCBI
26	Jiang H, Zhao L, Dong X, He A, Zheng C, Johansson M, Karlsson A and Zheng X: Tanshinone IIA enhances bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in nuclei and mitochondria. Oncol Rep. 34:1487–1493. 2015. View Article : Google Scholar : PubMed/NCBI
27	Ma S, Qu W, Mao L, Zhu Z, Jia L, Zhao L and Zheng X: Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer. Oncol Rep. 27:1443–1450. 2012.PubMed/NCBI
28	Qu W, Zhu Z, Zhao L, He A and Zheng X: Conditionally replicating adenovirus SG500-expressed mutant Dm-dNK gene for breast cancer therapy. Int J Oncol. 41:2175–2183. 2012. View Article : Google Scholar : PubMed/NCBI
29	Tang M, Zu C, He A, Wang W, Chen B and Zheng X: Synergistic antitumor effect of adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase and nucleoside analogs for human breast carcinoma in vitro and in vivo. Drug Des Devel Ther. 9:3301–3312. 2015.PubMed/NCBI
30	Zhang N, Dong X, Sun Y, Cai X, Zheng C, He A, Xu K and Zheng X: Cytotoxic effects of adenovirus- and lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase on Bcap37 breast cancer cells. Oncol Rep. 29:960–966. 2013. View Article : Google Scholar : PubMed/NCBI
31	Zhang N, Zhao L, Ma S, Gu M and Zheng X: Lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase driven by the hTERT promoter combined with gemcitabine: A potential strategy for cancer therapy. Int J Mol Med. 30:659–665. 2012. View Article : Google Scholar : PubMed/NCBI
32	Zheng X, Lundberg M, Karlsson A and Johansson M: Lipid-mediated protein delivery of suicide nucleoside kinases. Cancer Res. 63:6909–6913. 2003.PubMed/NCBI
33	Zhu Z, Ma S, Zhao L, Sun Z, He A, Xu H and Zheng X: Adenovirus-mediated Drosophila melanogaster deoxyribonucleoside kinase mutants combined with gemcitabine harbor a safe cancer treatment profile. Int J Oncol. 38:745–753. 2011.PubMed/NCBI
34	Ma S, Zhao L, Zhu Z, Liu Q, Xu H, Johansson M, Karlsson A and Zheng X: The multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster as a therapeutic suicide gene of breast cancer cells. J Gene Med. 13:305–311. 2011. View Article : Google Scholar : PubMed/NCBI
35	Sun X, Xu X, Chen Y, Guan R, Cheng T, Wang Y, Jin R, Song M and Hang T: Danggui buxue decoction sensitizes the response of non-small-cell lung cancer to gemcitabine via regulating deoxycytidine kinase and P-glycoprotein. Molecules. 24:20112019. View Article : Google Scholar
36	Sierzega M, Pach R, Kulig P, Legutko J and Kulig J: Prognostic implications of expression profiling for gemcitabine-related genes (hENT1, dCK, RRM1, RRM2) in patients with resectable pancreatic adenocarcinoma receiving adjuvant chemotherapy. Pancreas. 46:684–689. 2017. View Article : Google Scholar : PubMed/NCBI
37	Zheng X, Johansson M and Karlsson A: Nucleoside analog cytotoxicity and bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol. Biochem Biophys Res Commun. 289:229–233. 2001. View Article : Google Scholar : PubMed/NCBI
38	Yang J, Wu Y, Wang X, Xu L, Zhao X and Yang Y: Chemoresistance is associated with overexpression of HAX-1, inhibition of which resensitizes drug-resistant breast cancer cells to chemotherapy. Tumour Biol. 39:10104283176922282017. View Article : Google Scholar : PubMed/NCBI
39	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
40	Zheng X, Johansson M and Karlsson A: Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. J Biol Chem. 275:39125–39129. 2000. View Article : Google Scholar : PubMed/NCBI
41	Fraser SP, Salvador V, Manning EA, Mizal J, Altun S, Raza M, Berridge RJ and Djamgoz MBA: Contribution of functional voltage-gated Na⁺ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. Lateral motility. J Cell Physiol. 195:479–487. 2003. View Article : Google Scholar : PubMed/NCBI
42	Hosokawa M, Saito M, Nakano A, Iwashita S, Ishizaka A, Ueda K and Iwakawa S: Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine. Oncol Lett. 10:761–767. 2015. View Article : Google Scholar : PubMed/NCBI
43	Erin N, Grahovac J, Brozovic A and Efferth T: Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 53:1007152020. View Article : Google Scholar : PubMed/NCBI
44	Yang XL, Lin FJ, Guo YJ, Shao ZM and Ou ZL: Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways. Onco Targets Ther. 7:1033–1042. 2014.PubMed/NCBI
45	Triller N, Korosec P, Kern I, Kosnik M and Debeljak A: Multidrug resistance in small cell lung cancer: Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer. 54:235–240. 2006. View Article : Google Scholar : PubMed/NCBI
46	Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJM, van Groeningen CJ, Pinedo HM and Peters GJ: Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther. 1:371–376. 2002.PubMed/NCBI
47	Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, Shu J, He R, Zhang N, Chung W, et al: Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One. 6:e233722011. View Article : Google Scholar : PubMed/NCBI
48	Stordal B, Pavlakis N and Davey R: Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review. Cancer Treat Rev. 33:347–357. 2007. View Article : Google Scholar : PubMed/NCBI